Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
By Peregrine Pharmaceuticals, Inc
Nov 17, 2006, 22:32
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced initiation of patient treatment in its Phase lb clinical trial to evaluate its lead anti-phospholipid immunotherapy agent bavituximab given in combination with common cancer chemotherapy agents. The trial is expected to enroll up to 12 patients at three clinical sites in India.
"We are very pleased that patient dosing is underway in this clinical study of bavituximab in combination with commonly-used chemotherapy drugs because preclinical studies support the concept that chemotherapy and bavituximab should have synergistic anti-tumor effects," said Steven W. King, president and CEO of Peregrine. "We are encouraged that the regulatory and logistical requirements for initiating this trial have proceeded so smoothly and we look forward to working with our clinical sites to complete patient enrollment in this study over the next few months. We believe the results from this study, in combination with data from our ongoing U.S. cancer trial, will help support advancing bavituximab into Phase II combination therapy cancer trials in 2007."
The Phase Ib trial is designed to test the safety and tolerability of bavituximab over an 8-week administration period when given with standard chemotherapy regimens including docetaxel, gemcitabine and carboplatin/paclitaxel. These regimens are commonly used for treating major cancer types, including breast, lung and pancreatic cancer, and patients with these various types of cancer are potentially eligible for the trial. Study endpoints include safety and drug pharmacokinetics. Patients will also be evaluated for tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, although this assessment is not a formal endpoint of the study. Patients will be followed for an additional four weeks after their last dose of bavituximab and may continue with chemotherapy according to standard-of-care guidelines. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.
Preclinical studies have confirmed that bavituximab acts synergistically when administered in combination with chemotherapy in major tumor types. Preclinical studies presented at the AACR annual meeting showed the potential of a bavituximab equivalent plus chemotherapy or radiation to increase survival in resistant breast and brain cancer, a very positive result in these models of advanced disease. A study published in the International Journal of Cancer demonstrated that a bavituximab equivalent given in combination with gemcitabine showed encouraging efficacy in animal models of pancreatic cancer, including reductions in metastatic disease, and an article in Cancer Research reported that a bavituximab equivalent plus docetaxel inhibited tumor growth by 93% in a model of advanced breast cancer.
Bavituximab is currently in clinical trials in the U.S. for the treatment of solid tumors and chronic hepatitis C infection. Clinical data to date has shown that bavituximab is generally safe and well tolerated.
All rights reserved by www.rxpgnews.com